

Doc code: IDS

PTO/SB/08a (03-15)

Doc description: Information Disclosure Statement (IDS) Filed

Approved for use through 07/31/2016. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	15790584
	Filing Date	2017-10-23
	First Named Inventor	APT (deceased 26-06-2014)
	Art Unit	TBD
	Examiner Name	TBD R. Kosson
	Attorney Docket Number	28599-US-DIV[3]

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	4485173		1984-11-27	Gierhart	
	2	4916066		1990-04-10	Akimoto et al.	
	3	5130242		1992-07-14	Phycotech, Inc.	
	4	5244921		1993-09-14	Martek Corporation	
	5	5246841		1993-09-21	Yazawa et al.	
	6	5314812		1994-05-24	Mishima et al.	
	7	5340594		1994-08-23	Omegatech, Inc.	
	8	5340742		1994-08-23	Omegatech, Inc.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

9	5401646		1995-03-28	Shinmen et al.	
10	5547699		1996-08-20	Iizuka et al.	
11	5698244		1997-12-16	OmegaTech Inc.	
12	6180376	B1	2001-01-30	Zeneca Limited	
13	6248909	B1	2001-06-19	Suntory Limited	
14	6255505	B1	2001-07-03	Gist-Brocades B.V.	
15	6372460	B1	2002-04-16	Gladue et al.	
16	6399803	B1	2002-06-04	Omegatech Inc.	
17	6410282	B1	2002-06-25	Kumar et al.	
18	6441208		2002-08-27	DSM N.V.	
19	6451567	B1	2002-09-17	Barclay, William	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

20	6461839	B2	2002-10-08	Yokochi et al.	
21	6509178		2003-01-21	Suntory Ltd. Nagase & Co. Ltd. Nagase Chemtex Corp	
22	6531150	B1	2003-03-11	Sunohara et al.	
23	6566123	B1	2003-05-20	Barclay, William	
24	6579714	B1	2003-06-17	Hirabayashi et al.	
25	6582941	B1	2003-06-24	Director-General of Agency of Industrial Science;	
26	6607900	B2	2003-08-19	Martek Biosciences Boulder	
27	6677470	B2	2004-01-13	Saebo et al.	
28	6727373	B2	2004-04-27	Bijl et al.	
29	6746857	B2	2004-06-08	Higashiyama et al.	
30	6783951	B2	2004-08-31	Long, Thomas Veach	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

31	6812009	B2	2004-11-02	Martek Biosciences Corporation	
32	6844021	B2	2005-01-18	Koike et al.	
33	6846942	B2	2005-01-25	Rubin, David	
34	6905850	B	2005-06-14	Nippon Suisan Kaisha Ltd.	US equiv. of CN
35	7005280	B2	2006-02-28	Martek Biosciences Corporation	
36	7011962	B2	2006-03-14	Barclay, William	
37	7022512	B2		Martek Biosciences Corporation	
38	7259006	B2	2007-08-21	Fujifilm Corporation	
39	7709236	B2	2010-05-04	Akimoto et al.	
40	7723386	B2	2010-05-25	Akimoto et al.	
41	7741500	B2	2010-06-22	Monsanto Technology LLC	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

42	7767427	2010-08-03	Akimoto , et al.
43	7863026	2011-01-04	Komazawa , et al.

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20010041358	A1	2001-11-15	Yokochi et al.	
	2	20020001833		2002-01-03	Martek Biosciences Corporation	
	3	20020026063		2002-02-28	Unknown	
	4	20020123111	A1	2002-09-05	Gladue et al.	
	5	20030060509		2003-03-27	Mary van Elswyk	
	6	20030143659	A1	2003-07-31	Bijl et al	
	7	20030161864	A1	2003-08-28	Tanaka et al	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

8	20030161864		2003-08-28	Suntory Ltd.	
9	20030180898	A1	2003-09-25	Bailey et al.	
10	20040067574	A1	2004-04-08	Bijl et al.	
11	20040161831	A1	2004-08-19	Fuji Photo Film Co. Ltd.	
12	20040203120	A1	2004-10-14	Kumar et al.	
13	20040236128	A1	2004-11-25	Rubin, David	
14	20050019880	A1	2005-01-27	Raghukumar, et al.	
15	20050129831	A1	2005-06-16	Fabritius, Dirk	
16	20050170479	A1	2005-08-04	Kobzeff et al.	
17	20050202148	A1	2005-09-15	Streekstra et al	
18	20050287651	A1	2005-12-29	Akimoto et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

19	20060110806	A1	2006-05-25	Damude et al.	
20	20060115881		2006-06-01	E. I. DuPont De Nemours and Company	
21	20060141592	A1	2006-06-29	Sumida et al.	
22	20060286648	A1	2006-12-21	Bailey et al.	
23	20070003686	A1	2007-01-04	Martek Biosciences Corporation	
24	20070015263	A1	2007-01-18	Wumpelmann, Mogens	
25	20070054384	A1	2007-03-08	Rusing et al	
26	20070112071		2007-05-17	Bryhn et al.	
27	20070148315	A1	2007-06-28	Schaap et al.	
28	20070226814		2007-09-27	Kiy et al.	
29	20070269507	A1	2007-11-22	Sachetto et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.K/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

30	20070299134	A1	2007-12-27	Miller et al.	
31	20080009045	A1	2008-01-10	Komazawa et al.	
32	20080020033	A1	2008-01-24	Kawashima et al	
33	20080026103	A1	2008-01-31	Martek Biosciences Corp.	
34	20080032353	A1	2008-02-07	Behrens et al.	
35	20080038789	A1	2008-02-14	Higashiyama et al.	
36	20080076164	A1	2008-03-27	Cirpus et al	
37	20080107791	A1	2008-05-08	Martek Biosciences Corp.	
38	20080166781	A1	2008-07-10	Higashiyama et al.	
39	20080199923		2008-08-21	Martek Biosciences Corporation	
40	20080234377	A1	2008-09-25	Ellis, Lorie	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.K/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

41	20080292681	A1	2008-11-27	Pedrol et al.
42	20080311645	A1	2008-12-18	Higashiyama, Kenichi
43	20090004219		2009-01-01	Reinhart Boerner van Deuren P.C.
44	20090011012	A1	2009-01-08	
45	20090093543		2009-04-09	E. I. DuPont De Nemours and Company
46	20090099261	A1	2009-04-16	Bell et al.
47	20090117194	A1	2009-05-07	Burja et al.
48	20090192304		2009-07-30	Mart
49	20090304784	A1	2009-12-10	Mane et al.
50	20100099765	A1	2010-04-22	Chilton et al.
51	20100130610		2010-05-27	Keller et al.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.K/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

52	20100167359	A1	2010-07-01	Katano et al.	
53	20100178369	A1	2010-07-15	Arledge, Nicole Lee	
54	20100266564		2010-10-21	Martek Biosciences Corporation	
55	20100285105		2010-11-11	Unknown	
56	20110177031		2011-07-21	DSM IP Assets B.V.	
57					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS

Remove

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	CA2687523	CA	A1	2008-11-27	Martek Biosciences Corporation		
	2	CN1648233A	CN	A	2005-08-03	China Oceanographic Univ.		
	3	EP0252716	EP		1988-01-13	Suntory Limited		

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

4	EP0273708	EP		1988-07-06	Sagami Chemical Research Center		
5	EP0823475	EP		1996-04-17	Yamaguchi Biochemicals LTD, Suntory Limited		
6	EP1818410	EP	A1	2007-08-15	Suntory Limited		
7	WO01073099	EP		2001-10-04	Council of Scientific and Industrial Research		
8	WO1991007498	EP		1991-05-30	Phycotech Inc.		
9	WO1991014427	EP		1991-10-03	Martek Corporation		
10	WO1994008467	EP		1994-04-28	Omegatech Inc.		
11	WO1997037032	EP		1997-10-09	Gist Brocades		
12	WO2008049512	IB		2008-05-02	LONZA AG		
13	JP2005102680	JP	A2	2005-04-21	Fuji Photo Film Co., Ltd.		
14	WO2008027991	SG	A2	2008-03-06	Martek Biosciences Corporation		

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

15	WO1991007498	WO		1991-05-30	Phycotech Inc.		
16	WO2002092540	WO	A1	2002-11-21	Martek Biosciences Corporation		
17	WO2007006078	WO	A1	2007-01-18	Adelaide Research and Innovation Pty Ltd		
18	WO2007068997	WO	A2	2007-06-21	Avestha Gengraine Technologies Pvt. Ltd.		
19	WO2007069078	WO	A2	2007-06-21	Ocean Nutrition Canada Ltd		
20	WO2008067605	WO	A1	2008-06-12	Biomass Research & Refining Pty Ltd		
21	WO2009029793	WO	A1	2009-03-05	Martek Biosciences Corporation		
22	WO2010088700	WO	A1	2010-08-05	Martek Biosciences Corporation		
23	WO2010097809	WO	A2	2010-09-02	V. B. Medicare Pvt Ltd		
24							
If you wish to add additional Foreign Patent Document citation information please click the Add button						Add	
NON-PATENT LITERATURE DOCUMENTS						Remove	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	15790584
	Filing Date	2017-10-23
	First Named Inventor	APT (deceased 26-06-2014)
	Art Unit	TBD
	Examiner Name	TBD
	Attorney Docket Number	28599-US-DIV[3]

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Amendment and Response US10228843, USPTO, 2005	
	2	ASHFORD ET AL., Electroni Microscopy May Reveal Structure of DHA rich Oil within Schizochytrium, Lipids, 2000, 1377-1386, 35(12)	
	3	ATCC, ATCC Certificate of Deposits 27173, 2009, 27173, 27173-C, 27173-E and 27173-G	
	4	BAHNWEG, Final Report on the Identification of Thraustochytrid Strains MK27173 and MK27977, Expoert Qualifications of Dr. Gunther Bahnweg, 2008	
	5	BAJPAI ET AL., Optimization of Production of DHA by Thraustochytrium aureaum ATCC 34304, JAOCS, 1991, 509-514, 68(7)	
	6	BAJPAI ET AL., Production of DHA by Thraustochytrium aureum, Appl Microbiol Biotechnol, 1991, 706-710, 35	
	7	BARCLAY ET AL., Development of a DHA production technology using schizochytrium, Journal of the American Oil Chemists' Society, 2005	
	8	BERGE ET AL., Fatty Acids from Lipids of Marine Organisms: Molecular Biodiversity, Roles as Biomarkers, Biologically Active Compounds, and Economical Aspects, Adv. Biochem Engin/Technol, 2005, pgs. 49-125, Vol. 96	
	9	BOWLES ET AL., Long chain n-3 polyunsaturated fatty acid production by members of the marine protistan group the thraustochytrids: screening of isolates and optimisation of docosaheaxaenoic acid production, Journal of Biotechnology, 1999, 193-202, 70	
	10	BURJA ET AL., Isolation and Characterization of polyunsaturated fatty acid producing Thraustochytrium species: screening of strains and optimization of omega-3 production, Appl Microbiol Biotechnol, 2006, 1161-1169, 72	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

11	CHEN ET AL., Screening of Red Algae Filaments as a Potential Alternative Source of Eicosapentaenoic Acid, Marine Biotechnology, 2002, 189-192, 4
12	COHEN ET AL., Overproduction of γ -Linolenic and Eicosapentaenoic Acids by Algae, Plant Physiol, 1992, 569-572, 98
13	COHEN, ZVI, Production Potential of Eicosapentaenoic Acid by Monodus subterraneus, JAOCS, 1994, 941-945, 71(9)
14	EUROPEAN PATENT OFFICE, ISR and Written Opinion, PCT/US2009-001720, 2009
15	FAN ET AL., Eicosapentaenoic and docosahexaenoic acids production by and okara-utilizing potential of thraustochytrids, J. Ind. Microbiol. Biotechnol., 2001, 199-202, 4, Springer, England
16	FAN ET AL., Lipid Characterization of Mangrove Thraustochytrid-Schizochytrium mangrovei, Journal of Agricultural and Food Chemistry, 2007, A-E
17	FERNANDEZ ET AL., Modeling of Eicosapentaenoic Acid (EPA) Production from Phaeodactylum tricomutum Cultures in Tubular Photobioreactors. Effects of Dilution, Rate, Tube Diameter, and Solar Irradiance, Biotechnology and Bioengineering, 2000, 173-183, 68(2)
18	GENBANK, GenBank AB022109.1, Thraustochytrium aggregatum gene for 18S rRNA, 2001, http://www.ncbi.nlm.nih.gov/nuccore/5509888
19	GOLDSTEIN ET AL., Axenic Culture Studies of A new Marine Phycomycete processing an unusual type of asexual reproduction, Amer. Jour. Bot., 1964, 72-78, 51(1), Botanical Society of America, United States
20	HAMAM ET AL., Synthesis of Structured Lipids via Acidolysis of DHA Single Cell Oil (DHASCO) with Capric Acid, Journal of Agricultural and Food Chemistry, 2004, pgs. 2900-2906, 52, MX
21	HIGASHIYAMA ET AL., Production of Arachidonic acid by Mortierella Fungi, Biotechnol. Bioprocess Eng., 2002, 252-262, 7

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.K/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

22	HONDA ET AL., Molecular Phylogeny of Labyrinthulids and Thraustochytrids based on the Sequencing of 18S Ribosomal RNA Gene, Journal of Eukaryotic Microbiology, 1999, pgs. 637-647, 46(6)
23	HONDA ET AL., Schizochytrium limacinum sp. nov., a new thraustochytrid from a mangrove area in the west Pacific Ocean, Mycol Res., 1998, 43-448, 102(4), Cambridge University Press for the British Mycological Society, England
24	HORROCKS ET AL., health benefits of docosahexaenoic acid (DHA), Pharmacol Res., 1999, 211-225, 40(3), Academic Press, England
25	HUANG ET AL., Grouping Newly Isolated Docosahexaenoic Acid-Producing Thraustochytrids Based on Their Polyunsaturated Fatty Acid Profiles and Comparative Analysis of 18S rRNA Genes, Marine Biotechnology, 2003, 450-457, 5
26	HUANG ET AL., Profile of Polyunsaturated Fatty Acids Produced by Thraustochytrium sp. KK17-3, JAOCS, 2001, 605-610, 78:6, AOCS Press
27	HIDA ET AL., Improvement of Docosahexaenoic Acid Production in a Culture of Thraustochytrium Aureum by medium Optimization, J. Ferment. Bioeng., 1996, 76-78, 81(1), National Institute of Bio-Science and Human Technology, Japan
28	JEH ET AL., Lipid body formation by Thraustochytrium aureum (ATCC 34304) in response to cell age, Korean J. Chem. Eng., 2008, 1103-1109, 25(5)
29	JIANG ET AL., Fatty Acid Composition and Squalene Content of the Marine Microalga Schizochytrium mangrovei, J. Agric. Food Chem., 2004, 1196-1200, 52
30	KAMLANGDEE ET AL., Polyunsaturated fatty acids production by Schizochytrium sp. isolated from mangrove, J. Sci. Technol., 2003, 643-650, 25(5)
31	KENDRICK ET AL., Lipids of Selected Molds Grown for Production of n-3 and n-6 Polyunsaturated Fatty Acids, Department of Applied Biology, 1992, 15-20, 27(1)
32	KIY ET AL., Production of Docosahexaenoic Acid by the Marine Microalga, Ulkenia sp., Single Cell Oils, 2005, 99-106

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.K/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

33	LEANDER, Evaluation of two thraustochytrid isolates, MK27173 and MK27797 and Expert Qualifications of Dr. Celeste Leander, 2008
34	LEWIS T., Characterisation and application of Australian thraustochytrids, Thesis submitted in fulfillment of the requirements of the degree of Doctor of Philosophy to The University of Tasmania, 2001, I-169
35	LEWIS, ET AL., The Biotechnological Potential of Thraustochytrids, School of Agricultural Science, 1999, p. 580-587, Vol 1
36	LI ET AL., Production of docosahexaenoic acid by Thraustochytrium roseum, Journal of Industrial Microbiology, 1994, 238-241, 13
37	MEIRELES ET AL., Lipid Class Composition of the Microalga Pavlova Lutheri: Eicosapentaenoic and Docosahexaenoic Acids, Journal of Agricultural and Food Chemistry, 2003, 2237-2241, 51
38	MO ET AL., Development of a PCR strategy for thraustochytrid identification based on 189S rDNA sequence, Marine Biology, 2002, 883-889, 140, Springer, Germany
39	NAKAHARA ET AL., Production of Docosahexaenoic and Docosapentaenoic Acids by Schizochytrium sp. Isolated from Yap Islands, JAOCS, 1996, 1421-1426, 73(11)
40	PERVEEN, Biotechnology Letters, Isolation and characterization of a novem thraustochytrid-like microorganism that efficiently produces docosahexaenoic acid, 2006, pages 197-202, 28
41	PORTER ET AL., Phylum Labyrinthulomycota, Handbook of Protoctista, 1989, 388-398, Jones and Barlett, Boston
42	RAGAN ET AL., Protistan parasite QPX of hard-shell clam Mercenaria mercenaria is a member of Labyrinthulomycota, Dis Aquat. Org., 2000, 185-190, 42, Inter-Research, Germany
43	RAGHUKUMAR, Thraustochytrid Marine Protists: Production of PUFAs and Other Emerging Technologies, Mar. Biotechnol., 2008, 631-640, 10, Springer, Germany

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.K/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

44	ROCHE, HELEN M., Unsaturated Fatty Acids, Proceedings of the Nutrition Society, 1999, p. 397-401, Vol. 58
45	RYAN ET AL, American Journal of Therapeutics, Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors, 2009, 183-192, 16
46	RYAN ET AL., Clinical Overview of Algal-Docosahexaenoic Acid: Effects on Triglyceride Levels and Other Cardiovascular Risk Factors, Am. J. Therap., 2009, 183-192, 16, Lippincott Williams & Wilkins, United States
47	SAKATA ET AL., Colony formation and fatty acid composition of marine labyrinthulid isolates grown on agar media, Fisheries Science, 2000, 84-90, 66, CN
48	SANDERS ET AL., Influence of an algal triacylglycerol containing docosahexaenoic acid and docosapentaenoic acid on cardiovascular risk factors in healthy men and women, British Journal of Nutrition, 2006, 525-531, 95, SG
49	SCIENCE DAILY, Biofuel Development Shifting from Soil to Sea, Specifically to Marine Algae, Science Daily, 2009, http://www.sciencedaily.com/releases/2008/12/081220084424.html , published January 4, 2009
50	SIMOPOULOS, Omega-3 Fatty Acids in Inflammation and Autoimmune Diseases, J. Am. Col. Nutr., 2002, 495-505, 21 (6), American College of Nutrition, United States
51	SINGH ET AL., Docosahexaenoic acid production by Thraustochytrium sp. ATCC 20892, World J. Microbiol. Biotechnol, 1996, 76-81, 12, Rapid Science Publishers, United States
52	SINGH ET AL., Essential Fatty Acids, DHA and Human Brain, Indian J. pediatr., 2005, 239-242, 72
53	SINGH ET AL., Microbial Production of Docosahexaenoic Acid, Adv. Appl. Microbial, 1997, 271-312, 45
54	SINGH ET AL., Production of high yields of docosahexaenoic acid Thraustochytrium roseum ATCC 28210, J. Indust. Microbiol, 1996, 370-373, 16, Society for Industrial Microbiology, United States

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.K/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

55	ULKEN, Two New Thraustochytriidae from the Outer Weser Estuary, 1965, 289-295, 9
56	ULKEN, Zwei neue Thraustochytien aus der Außenweser, Veröffentlichungen des Institut für Meeresforschung in Bremerhaven, 1965, 289-295, 9
57	VAZHAPPILLY ET AL., Eicosapentaenoic Acid and Docosahexaenoic Acid Production Potential of Microalgae and their Heterotrophic Growth, JAOCS, 1998, 393-397, 75(3)
58	WARD ET AL., Omega-3/6 fatty acids: Alternative sources of production, Process Biochemistry, 2005, 3627-3652, 40, Elsevier
59	WATANABE ET AL., Production of c-Labeled Docosahexaenoic Acid by a Thraustochytrid, J. Jpn. Oil Chem. Soc., 2000, 1437-1441, 49, No 11/12
60	WEN ET AL., Heterotrophic production of eicosapentaenoic acid by microalgae, Biotechnology Advances, 2003, 273-294, 21
61	WESTEROP, Biomolecular Engineering, Basics and Applications, 2003, page 37-82, 20
62	XU ET AL., Growth characteristics and eicosapentaenoic acid production by Nannochloropsis sp. in mixotrophic conditions, Biotechnology Letters, 2004, 51-53, 26
63	YAGUCHI ET AL., Production of high yields of docosahexaenoic acid by Schizochytrium sp. Strain SR21, JAOCS, 1997, 1431-1434, 74(11)
64	YOKOYAMA ET AL., Taxonomic rearrangement of the genus Ulkenia sensu lato based on morphology, chemotaxonomical characteristics, and 18S rRNA gene phylogeny, Mycoscience, 2007, p. 329-341, Vol. 48
65	YONGMANITCHAI ET AL., Omega-3 Fatty Acids: Alternative Sources of Production, Process Biochemistry, 1989, 117-125, 24, Elsevier, United States

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.K/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

66	ZELLER ET AL., Production of Docosaheaxaenoic Acid from Microalgae, ACS Symposium Series, 2001, 108-124, 9, American Chemical Society	
67	ZHANG ET AL., Studies on Cell Oil Produced by Schizochytrium sp. FJU-512, Journal of Fujian Normal University, Mar 2007, 75-80, 23(2)	×

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/ROSANNE KOSSON/	Date Considered	03/13/2019
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15790584
Filing Date	2017-10-23
First Named Inventor	APT (deceased 26-06-2014)
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	28599-US-DIV[3]

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Xi Chen/	Date (YYYY-MM-DD)	2018-07-27
Name/Print	Xi Chen	Registration Number	61380

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.K/~~